



Corrigendum: Upregulation of CCT-3 Induces Breast Cancer Cell Proliferation Through miR-223 Competition and Wnt/b-Catenin Signaling Pathway Activation

Hongbo Qu^{1*}, Fang Zhu², Huaying Dong³, Xiongqiang Hu¹ and Mingli Han⁴

¹ Department of Breast and Thyroid Surgery, The First People's Hospital of Chenzhou, Chenzhou, China, ² Department of Breast Health Center, The First People's Hospital of Chenzhou (South Hospital), Chenzhou, China, ³ Department of General Surgery, Hainan General Hospital, Hainan Medical University, Haikou, China, ⁴ Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

OPEN ACCESS

Edited and reviewed by:

Marie R. Webster,
Lankenau Institute for Medical
Research, United States

*Correspondence:

Hongbo Qu
quhongbo_2020@163.com

Specialty section:

This article was submitted to
Cancer Molecular Targets
and Therapeutics,
a section of the journal
Frontiers in Oncology

Received: 12 April 2022

Accepted: 19 April 2022

Published: 19 May 2022

Citation:

Qu H, Zhu F, Dong H, Hu X and Han M
(2022) Corrigendum: Upregulation of
CCT-3 Induces Breast Cancer Cell
Proliferation Through miR-223
Competition and Wnt/b-Catenin
Signaling Pathway Activation.
Front. Oncol. 12:917378.
doi: 10.3389/fonc.2022.917378

Keywords: ceRNA, miR-223, Wnt/b-catenin, breast cancer, CCT-3

A Corrigendum on

Upregulation of CCT-3 Induces Breast Cancer Cell Proliferation Through miR-223 Competition and Wnt/ β -Catenin Signaling Pathway Activation

By Qu H, Zhu F, Dong H, Hu X and Han M (2020). *Front. Oncol.* 10:533176. doi: 10.3389/fonc.2020.533176

In the original article, there was a mistake in **Figure 2F** as published. A mistake was done during the adjustment of tumor formation data due to the unfamiliar with the software. The corrected **Figure 2** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Qu, Zhu, Dong, Hu and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 2 | CCT-3 promotes breast cancer cell proliferation and tumorigenicity in vitro and in vivo. **(A)** Protein levels of CCT-3 expression in CCT-3-overexpressed and CCT-3-silenced cells. MTT assays **(B, C)**, colony formation assay **(D)**, and flow cytometric analysis **(E)** indicated that the growth rates increased in CCT-3-overexpressed cells and decreased in CCT-3-silenced cells. The cells were arrested in G2/M phase when CCT-3-silenced. Values are mean \pm SD of three independent experiments. ## $p < 0.01$ (OE vs. OE-NC), *** $p < 0.001$ (siRNA vs. siRNA-NC), t-test. **(F)** Tumors derived from the vector-infected and the CCT-3-silenced cells. Representative images of tumor growth (left). Tumor volume growth curves (middle). Mean tumor weight (right) at 28 days after inoculation. * $p < 0.05$, t-test.